Osborn JW, Foss JD
Male HFD-fed Glp1r fl/fl control mice and Glp1r Wnt1/ mice were treated IP with either vehicle or mGIPR-Ab/P1 every 6 days for 18 days
The case study is available here
( 3.3 Development of unimolecular agents targeting both GIPR and GLP-1R The anti-obesity effects of GIPR antagonism antibody, both alone and in combination with GLP-1RAs, have been demonstrated in preclinical models of mice and monkeys (68, 73)
Although liraglutide treatment led to a decrease in pro-inflammatory microbial species (e.g., EscherichiaShigella, Megamonas , and Bacillus ) in DM2 patients, no statistically significant differences were observed when compared to metformin treatment
Consultation with a hepatologist is appropriate for patients with advanced liver disease, decompensation signs, or uncertain diagnoses